Related references
Note: Only part of the references are listed.Lenalidomide: what is the right dose in CLL?
Thomas S. Lin
BLOOD (2008)
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Alessandra Ferrajoli et al.
BLOOD (2008)
Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia
Jiezhong Chen et al.
CANCER BIOLOGY & THERAPY (2008)
Immunomodulatory drugs Revlimid (R) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
Dan Zhu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
S. Vincent Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The ratio of cyclin D1/p21kip baseline gene expression and SPARC gene expression can be potential predictors of non-Hodgkin's lymphoma (NHL) patient response to lenalidomide therapy
L. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
Leslie A. Andritsos et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Immunomodulatory therapy for myelodysplastic syndromes
Lubomir Sokol et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Immunomodulatory drugs in the treatment of myelodysplastic syndromes
Jose Ortega et al.
CURRENT OPINION IN ONCOLOGY (2007)
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma
David P. Mangiameli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Andrea Pellagatti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma
Marc Beyer et al.
BLOOD (2006)
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma
ZZ Yang et al.
BLOOD (2006)
Regulatory T cells, tumour immunity and immunotherapy
WP Zou
NATURE REVIEWS IMMUNOLOGY (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-θ activation and enhancing the DNA-binding activity of AP-1 but not NF-κB, OCT-1, or NF-AT
F Payvandi et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia
M Motta et al.
LEUKEMIA (2005)
Thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer
LS Downs et al.
GYNECOLOGIC ONCOLOGY (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Toward an understanding of NKT cell biology: Progress and paradoxes
M Kronenberg
ANNUAL REVIEW OF IMMUNOLOGY (2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
K Dredge et al.
MICROVASCULAR RESEARCH (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
JB Bartlett et al.
BRITISH JOURNAL OF CANCER (2004)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
R LeBlanc et al.
BLOOD (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
SA Schey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Focus on myeloproliferative diseases and myelodysplastic syndromes
RA Van Etten et al.
CANCER CELL (2004)
Foxp3: a critical regulator of the development and function of regulatory T cells
S Hori et al.
MICROBES AND INFECTION (2004)
Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta
K Fujita et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2004)
Response to thalidomide in multiple myeloma:: impact of angiogenic factors
L Rosiñol et al.
CYTOKINE (2004)
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs
PH Schafer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
CD25+ regulatory T cells and tumor immunity
E Jones et al.
IMMUNOLOGY LETTERS (2003)
Bone marrow angiogenesis and progression in multiple myeloma: Clinical significance and therapeutic approach
V Eleutherakis-Papaiakovou et al.
LEUKEMIA & LYMPHOMA (2003)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
K Dredge et al.
BRITISH JOURNAL OF CANCER (2002)
New aspects of natural-killer-cell surveillance and therapy of cancer
MJ Smyth et al.
NATURE REVIEWS CANCER (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
UK Liyanage et al.
JOURNAL OF IMMUNOLOGY (2002)
Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade
JL Xu et al.
JOURNAL OF CLINICAL PATHOLOGY (2002)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
K Neben et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344)
D Onat et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Share Paper
